AI Engines For more Details: Perplexity Kagi Labs You
Antihistamine Effects: Methapyrilene hydrochloride blocks the action of histamine, a chemical produced by the body in response to allergens. By blocking histamine receptors, it helps alleviate symptoms of allergic reactions, such as itching, sneezing, and runny nose.
Anticholinergic Effects: Methapyrilene hydrochloride also has anticholinergic properties, meaning it inhibits the activity of acetylcholine, a neurotransmitter in the nervous system. This can lead to side effects such as dry mouth, blurred vision, constipation, urinary retention, and confusion.
Sedative Effects: Methapyrilene hydrochloride has sedative effects and was often used in over-the-counter sleep aids and nighttime cold remedies. However, these sedative effects can also contribute to drowsiness and impair cognitive and motor function, potentially increasing the risk of accidents and falls.
Safety Concerns: Methapyrilene hydrochloride has been associated with serious safety concerns, including reports of liver toxicity and adverse effects on the heart, such as arrhythmias. Due to these safety issues, the medication has been withdrawn from many markets and is no longer recommended for use.
Withdrawal from the Market: In the United States, methapyrilene hydrochloride was withdrawn from the market in the 1970s due to safety concerns. Other countries have also restricted or discontinued its use.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.6 | 0.4 | 0.5 |
| ADHD | 2.6 | 0.9 | 1.89 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1 | 1 | 0 |
| Allergies | 1.7 | 1.2 | 0.42 |
| Allergy to milk products | 1 | 0.6 | 0.67 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 2 | 3.6 | -0.8 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.4 | 3.25 |
| Ankylosing spondylitis | 1.8 | 0.6 | 2 |
| Anorexia Nervosa | 0.7 | 2.1 | -2 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 3.4 | 2.3 | 0.48 |
| Atherosclerosis | 0.6 | 0.8 | -0.33 |
| Atrial fibrillation | 2.2 | 0.8 | 1.75 |
| Autism | 4.1 | 4 | 0.02 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.6 | 1.4 | -1.33 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Cancer (General) | 0.6 | 0.7 | -0.17 |
| Carcinoma | 1.6 | 1 | 0.6 |
| Celiac Disease | 1.2 | 1.9 | -0.58 |
| Cerebral Palsy | 1.3 | 1 | 0.3 |
| Chronic Fatigue Syndrome | 2.6 | 2.1 | 0.24 |
| Chronic Kidney Disease | 1.1 | 1.7 | -0.55 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 0.6 | 0.4 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1 | -2.33 |
| Cognitive Function | 1.7 | 1.4 | 0.21 |
| Colorectal Cancer | 3.5 | 1.4 | 1.5 |
| Constipation | 0.6 | 0.7 | -0.17 |
| Coronary artery disease | 0.6 | 2 | -2.33 |
| COVID-19 | 4.1 | 4.9 | -0.2 |
| Crohn's Disease | 2.9 | 3.2 | -0.1 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 1.2 | 1.1 | 0.09 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 4.6 | 4.4 | 0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.6 | 0.8 | -0.33 |
| Endometriosis | 1.3 | 1.7 | -0.31 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.2 | 1.3 | -0.08 |
| erectile dysfunction | 0.4 | 0.3 | 0.33 |
| Fibromyalgia | 1.3 | 0.6 | 1.17 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 1.8 | 0.28 |
| gallstone disease (gsd) | 0.4 | 1 | -1.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.9 | -2 |
| Generalized anxiety disorder | 1.5 | 2.1 | -0.4 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.5 | 2 |
| Graves' disease | 0.9 | 2.1 | -1.33 |
| Gulf War Syndrome | 0.7 | 1 | -0.43 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 1.9 | 1.2 | 0.58 |
| Heart Failure | 1.2 | 1.4 | -0.17 |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.4 | -0.33 |
| hyperglycemia | 0.8 | 1.3 | -0.63 |
| Hyperlipidemia (High Blood Fats) | 0.5 | 0.5 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 2 | 3.1 | -0.55 |
| Hypothyroidism | 0.2 | 1 | -4 |
| Hypoxia | 0.8 | 0.3 | 1.67 |
| IgA nephropathy (IgAN) | 0.9 | 2 | -1.22 |
| Inflammatory Bowel Disease | 3.2 | 4.3 | -0.34 |
| Insomnia | 1.4 | 2.7 | -0.93 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.4 | 0.6 | -0.5 |
| Irritable Bowel Syndrome | 2.9 | 3.3 | -0.14 |
| ischemic stroke | 1.6 | 1.1 | 0.45 |
| Liver Cirrhosis | 3.5 | 3.2 | 0.09 |
| Long COVID | 3 | 3.6 | -0.2 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.1 | 0.5 | -4 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 1.2 | 0.6 | 1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.7 | 0.29 |
| Metabolic Syndrome | 2.8 | 3.7 | -0.32 |
| Mood Disorders | 5 | 4 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 2.5 | 2.3 | 0.09 |
| Multiple system atrophy (MSA) | 0.7 | 0.4 | 0.75 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 1.9 | -5.33 |
| Neuropathy (all types) | 0.9 | 0.6 | 0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 3.5 | -0.52 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 4.4 | 4.6 | -0.05 |
| obsessive-compulsive disorder | 1.9 | 2.4 | -0.26 |
| Osteoarthritis | 0.8 | 1.1 | -0.38 |
| Osteoporosis | 1.4 | 1.1 | 0.27 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 4.1 | 3 | 0.37 |
| Polycystic ovary syndrome | 2.2 | 2 | 0.1 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | |
| primary biliary cholangitis | 0.6 | 0.3 | 1 |
| Primary sclerosing cholangitis | 0.9 | 0.8 | 0.13 |
| Psoriasis | 1.2 | 1.7 | -0.42 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 2.3 | 0.22 |
| Rosacea | 0.4 | 0.8 | -1 |
| Schizophrenia | 3.1 | 2.3 | 0.35 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 1.1 | 1.1 | 0 |
| Sleep Apnea | 1 | 1.5 | -0.5 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.2 | 5 |
| Stress / posttraumatic stress disorder | 1.3 | 2.4 | -0.85 |
| Systemic Lupus Erythematosus | 1.9 | 1.5 | 0.27 |
| Tic Disorder | 0.6 | 0.3 | 1 |
| Tourette syndrome | 0.5 | 0.3 | 0.67 |
| Type 1 Diabetes | 2.1 | 2.3 | -0.1 |
| Type 2 Diabetes | 3 | 3.2 | -0.07 |
| Ulcerative colitis | 1.7 | 2.9 | -0.71 |
| Unhealthy Ageing | 1.6 | 1.8 | -0.13 |
| Vitiligo | 1.2 | 0.5 | 1.4 |
